Back to top
more

EyePoint Pharmaceuticals (EYPT)

(Delayed Data from NSDQ)

$12.94 USD

12.94
978,077

+0.49 (3.94%)

Updated May 15, 2024 04:00 PM ET

After-Market: $12.92 -0.02 (-0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

EyePoint Pharmaceuticals (EYPT) Soars 21.6%: Is Further Upside Left in the Stock?

EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

EyePoint Pharmaceuticals (EYPT) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

EyePoint Pharmaceuticals (EYPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

GSK to Boost Vaccine Portfolio With Affinivax Acquisition

GSK signs an agreement to acquire Affinivax, Inc. for a $2.1 billion upfront payment. The company is looking to boost its vaccine pipeline with this acquisition.

AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate

AbbVie (ABBV) submits a new drug application to the FDA for ABBV-951, which has been developed for treating advanced Parkinson's disease.

Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.

Horizon (HZNP) Begins Enrollment in Alopecia Areata Study

Horizon (HZNP) enrolls the first patient in a phase II study evaluating daxdilimab (HZN-7734) for the treatment of alopecia areata.

Seagen's (SGEN) Stock Up on CEO's Resignation Announcement

Seagen's (SGEN) current chief executive officer and president, Clay Siegall, announces his resignation. The company is looking for a new CEO. Stock up.

Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia

The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.

Down 18.2% in 4 Weeks, Here's Why You Should You Buy the Dip in EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals (EYPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -4% and 10.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -18% and 14.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Reports Q4 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 0% and 0.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -23.40% and -5.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma

The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma

Riya Anand headshot

4 Stocks to Keep a Watch on Amid Growing Optical Care Demand

Stocks like Alcon (ALC), National Vision (EYE), The Cooper Companies (COO) and EyePoint Pharmaceuticals (EYPT) are gaining momentum amid rising optical care demand.

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 22.22% and 2.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Misses Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 5.66% and -11.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Will EyePoint Pharmaceuticals (EYPT) Report Negative Q1 Earnings? What You Should Know

EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -324.44% and -70.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks.com featured highlights include: Stamps.com, Ribbon Communications, American Software and EyePoint Pharmaceuticals

Zacks.com featured highlights include: Stamps.com, Ribbon Communications, American Software and EyePoint Pharmaceuticals

Shrabana Mukherjee headshot

4 Stocks in the Limelight on New Analyst Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Stamps.com Inc. (STMP), Ribbon Communications Inc. (RBBN), American Software, Inc. (AMSWA) and EyePoint Pharmaceuticals, Inc. (EYPT).

Will Walgreens Boots' (WBA) Retail Arm Be Dull in Q1 Earnings?

Walgreens Boots' (WBA) retail pharmacy international sales are likely to remain dull in Q1 on difficult market scenario in the United Kingdom.

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Tops Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -200.00% and 0.22%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

EyePoint Pharmaceuticals (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.